Clinical Trial Update: Effect of Sarpogrelate, a Serotonin Receptor Antagonist, on Coronary Artery Disease [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating Sarpogrelate, a serotonin receptor antagonist, for coronary artery disease has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Sarpogrelate (sarpogrelate)

Snippet

Sponsor: Seoul National University Bundang Hospital | Conditions: Coronary Artery Disease | Phase 4 | Status: COMPLETED